Publications by authors named "Emil A Tanghetti"

Claim this Profile
C
Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by Age.
Leon H Kircik, Julie C Harper, Hilary Baldwin, Lawrence F Eichenfield, Emil A Tanghetti

J Drugs Dermatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and Tazarotene.
Emil A Tanghetti, Mark G Lebwohl, Linda Stein Gold, Lawrence Green, Zoe D Draelos

J Drugs Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% for Acne: Results From A 6-Month Open-Label Study.
Zoe Diana Draelos, Mahmoud Ghannoum, Linda Stein Gold, Julie C Harper, Hilary Baldwin, Emil A Tanghetti

J Drugs Dermatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Acne With a 1726 nm Laser, Air Cooling, and Real-Time Temperature Monitoring, Software-Assisted Power Adjustment to Achieve a Temperature Endpoint With Selective Sebaceous Gland Photothermolysis.
Emil A Tanghetti, Rafael Sierra, Michael Estes, Aubrey Eck, Alfred Intintoli

Lasers Surg Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents.
Lawrence F Eichenfield, Adelaide A Hebert, Julie C Harper, Hilary Baldwin, Neal Bhatia, Emil A Tanghetti

J Drugs Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rosacea Core Domain Set for Clinical Trials and Practice: A Consensus Statement.
McKenzie A Dirr, Areeba Ahmed, Daniel I Schlessinger, Misha Haq, Victoria Shi, Emil A Tanghetti

JAMA Dermatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
Leon H Kircik, Linda Stein Gold, Michael Gold, Jonathan S Weiss, Julie C Harper, Emil A Tanghetti

Dermatol Ther (Heidelb)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.
Emil A Tanghetti, Joshua A Zeichner, Michael Gold, Neil Sadick, Fran E Cook-Bolden

J Dermatolog Treat· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials.
Zoe D Draelos, Emil A Tanghetti, Leon H Kircik, Neal Bhatia, Joshua A Zeichner

J Dermatolog Treat· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne.
Jerry Tan, Zoe D Draelos, Melinda J Gooderham, Andrew F Alexis, Emmy Graber, Emil A Tanghetti

J Clin Aesthet Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
Lawrence F Eichenfield, Linda Stein Gold, Leon H Kircik, William P Werschler, Kenneth Beer, Emil A Tanghetti

Pediatr Dermatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in Psoriatic Disease Addressed by Fixed-Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion.
Leon Kircik, Emil A Tanghetti, Adam Friedman, Kristine Kucera, Abby Jacobson

J Clin Aesthet Dermatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Linda Stein Gold, Hilary Baldwin, Leon H Kircik, Jonathan S Weiss, David M Pariser, Emil A Tanghetti

Am J Clin Dermatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits.
Mark G Lebwohl, Emil A Tanghetti, Linda Stein Gold, James Q Del Rosso, Nelly K Gilyadov

Dermatol Ther (Heidelb)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
Emil A Tanghetti, Neal Bhatia, Scott Drew, Abby Jacobson

J Drugs Dermatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
Emil A Tanghetti, Linda Stein Gold, James Q Del Rosso, Tina Lin, Arturo Angel

J Dermatolog Treat· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.
Lawrence J Green, James Q Del Rosso, Emil A Tanghetti, Eric Guenin

J Drugs Dermatol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study.
Emil A Tanghetti, David J Goldberg, Jeffrey S Dover, Roy G Geronemus, Zane Bai

Lasers Surg Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
Lawrence F Eichenfield, Emil A Tanghetti, Eric Guenin, Gina Martin, Radhakrishnan Pillai

J Drugs Dermatol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
Emil A Tanghetti, William Philip Werschler, Edward Lain, Eric Guenin, Susan Harris

J Drugs Dermatol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
Emil A. Tanghetti, William P. Werschler, Terry Lain, Eric Guenin, Gina Martin

J Drugs Dermatol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
Emil A. Tanghetti, Leon H. Kircik, Lawrence J. Green, Eric Guenin, Susan Harris

J Drugs Dermatol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.
Jeffrey L Sugarman, Jonathan S Weiss, Emil A Tanghetti, Jennifer Soung, Paul S Yamauchi

Cutis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Jeffrey L Sugarman, Jonathan Weiss, Emil A Tanghetti, Jerry Bagel, Paul S Yamauchi

J Drugs Dermatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
Emil A Tanghetti, Jeffrey S Dover, David J Goldberg, Sunil S Dhawan, Lei Luo

J Drugs Dermatol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis